Articles

Editor's Letter

Published on 17 December 2014

Fourth and final issue of GaBI Journal’s third volume

The interest in the development, regulatory approval, use, and post-marketing surveillance of generic and biosimilar pharmaceutical products continues to increase; as illustrated by the tremendous number of views (over 1,028,324...

Author(s): Professor Philip D Walson, MD

DOI: 10.5639/gabij.2014.0304.036

3.799 views

Read more →

Abstracted Scientific Content

Published on 10 July 2018

EU risk-sharing agreements between 2000−2015

Submitted: 20 June 2018; Revised: 14 August 2018; Accepted: 18 August 2018; Published online first: 31 August 2018 The ageing population, longer life expectancies, and the increasing cost of drugs...

Author(s): GaBI Journal Editor

DOI: 10.5639/gabij.2018.0703.026

3.757 views

Read more →

Editor's Letter

Published on 26 March 2015

Editor’s introduction to the initial issue of the fourth volume of GaBI Journal

This first 2015 GaBI Journal issue (fourth volume of the journal) is being published soon after the first US biosimilar approval and it contains a number of articles that illustrate...

Author(s): Professor Philip D Walson, MD

DOI: 10.5639/gabij.2015.0401.001

3.725 views

Read more →

Abstracted Scientific Content

Published on 01 June 2018

A call for coherence in EU legislation to promote generics

Submitted: 6 May 2018; Revised: 7 May 2018; Accepted: 8 May 2018; Published online first: 18 May 2018 Data and market exclusivity for originator medicines in the European Union (EU)...

Author(s): GaBI Journal Editor

DOI: 10.5639/gabij.2018.0702.019

3.700 views

Read more →

Editor's Letter

Published on 16 September 2015

Latest features in GaBI Journal, 2015, Issue 3

This issue of the journal contains a number of manuscripts that discuss proposals to simplify the evaluation of, and therefore decrease the cost of developing, follow-on biological products. These controversial...

Author(s): Professor Philip D Walson, MD

DOI: 10.5639/gabij.2015.0403.022

3.640 views

Read more →

Published on 16 October 2014

2012/1 GaBI Journal Table of Contents

Contents Editor's Letter Introduction to the GaBI Journal Editorial Generic medicine pricing: on track in Europe? Commentary Innovator companies should focus on innovations Review Article A review of generic medicine...

3.569 views

Read more →

Editor's Letter

Published on 15 June 2015

What to look forward to in GaBI Journal, 2015, Issue 2

This entire issue of the GaBI Journal could be titled ‘World News’ since it contains manuscripts describing global generics and biosimilar activities. The Commentary by Leng et al. describes regulatory...

Author(s): Professor Philip D Walson, MD

DOI: 10.5639/gabij.2015.0402.013

3.537 views

Read more →

Abstracted Scientific Content

Published on 22 June 2021

An IPRP survey of the regulatory requirements for the waiver of in vivo bioequivalence studies of generic medicinal products in certain dosage forms

Submitted: 14 May 2021; Revised: 14 May 2021; Accepted: 3 June 2021; Published online first: 10 June 2021 Medicines regulatory authorities aim to address rising healthcare costs and promote access...

Author(s): Alfredo García Arieta, PhD, Clare Rodrigues

DOI: 10.5639/gabij.2021.1003.019

3.535 views

Read more →

Thank you to reviewers

Published on 15 March 2017

Thank you to reviewers 2016

The editors and publisher wish to express their gratitude to the colleagues listed below for their valuable contribution to the peer review process for the Generics and Biosimilars Initiative Journal...

3.525 views

Read more →

Published on 22 October 2014

2013/2 GaBI Journal Table of Contents

Contents Editor's Letter What to look forward to in GaBI Journal, 2013, Issue 2 Editorial National and regional activities by sickness funds in Austria to encourage the rational use of...

3.516 views

Read more →

Editor's Letter

Published on 14 August 2019

Unmet potential of Generics and Biosimilars to reduce healthcare costs

The high cost of pharmaceuticals has been gaining increasing attention as a threat to both healthcare systems and patients’ access to care globally. This GaBI issue contains articles focusing on...

Author(s): Professor Philip D Walson, MD

DOI: 10.5639/gabij.2019.0802.006

3.501 views

Read more →

Original Research

Published on 11 January 2024

Pharmacokinetic bioequivalence studies of a new Etoricoxib tablet formulation developed using proprietary MiST technology — risk assessment and mitigation using GastroPlus software

Author byline as per print journal: Dhananjay Panigrahi1, MPharm; Aditya Murthy2, MPharm, PhD; Shubham Jamdade2, MPharm; Manoj Gundeti2, MPharm; Nagarjun Rangaraj1, MPharm, PhD; Anup Avijit Choudhury1, MPharm; Tausif Ahmed2, MPharm,...

etoricoxib, GastroPlus®, modelling and simulation, PBBM, spray granulation, virtual bioequivalence

DOI: 10.5639/gabij.2024.1301.003

3.497 views

Read more →